L Lee Dupuis1,2, Lillian Sung3,4, Alexander Molassiotis5, Andrea D Orsey6,7, Wim Tissing8, Marianne van de Wetering9. 1. Department of Pharmacy and Research Institute, The Hospital for Sick Children, 555 University Ave, Toronto, ON, M5G 1X8, Canada. lee.dupuis@sickkids.ca. 2. Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada. lee.dupuis@sickkids.ca. 3. Department of Pediatrics and Research Institute, The Hospital for Sick Children, Toronto, Canada. 4. Faculty of Medicine, University of Toronto, Toronto, Canada. 5. School of Nursing and WHO Collaborating Centre for Community Health Services, The Hong Kong Polytechnic University, Hong Kong, China. 6. Division of Pediatric Hematology/Oncology, Connecticut Children's Medical Center, Hartford, CT, USA. 7. Department of Pediatrics, University of Connecticut School of Medicine, Farmington, CT, USA. 8. Department of Pediatric Oncology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands. 9. Department of Paediatric Oncology, Emma Children's Hospital/Academic Medical Center, Amsterdam, Netherlands.
Abstract
PURPOSE: To update the 2009 recommendations for the prevention of acute chemotherapy-induced emesis in children. METHODS: We updated the original systematic literature search. Randomized studies were included in the evidence to support this guideline if they were primary studies fully published in full text in English or French; included only children less than 18 years old or, for mixed studies of adults and children, reported the pediatric results separately or the median or mean age was no more than 13 years; evaluated acute chemotherapy-induced nausea and vomiting (CINV) prophylaxis; provided sufficient information to permit determination of the emetogenicity of the antineoplastic therapy administered or the study investigators stated the emetogenicity of the chemotherapy administered; included an implicit or explicit definition of complete acute CINV response; described the antiemetic regimen in full; and reported the complete acute CINV response rate as a proportion. RESULTS: Twenty-five randomized studies, including eight published since 2009, met the criteria for inclusion in this systematic review. Prophylaxis with a 5-HT3 antagonist (granisetron or ondansetron or palonosetron or tropisetron) ± dexamethasone ± aprepitant is recommended for children receiving highly or moderately emetogenic chemotherapy. For children receiving chemotherapy of low emetogenicity, a 5-HT3 antagonist is recommended. CONCLUSIONS: The findings of several randomized trials were used to update recommendations for the prevention of acute CINV. However, significant research gaps remain and must be addressed before CINV control in children can be optimized.
PURPOSE: To update the 2009 recommendations for the prevention of acute chemotherapy-induced emesis in children. METHODS: We updated the original systematic literature search. Randomized studies were included in the evidence to support this guideline if they were primary studies fully published in full text in English or French; included only children less than 18 years old or, for mixed studies of adults and children, reported the pediatric results separately or the median or mean age was no more than 13 years; evaluated acute chemotherapy-induced nausea and vomiting (CINV) prophylaxis; provided sufficient information to permit determination of the emetogenicity of the antineoplastic therapy administered or the study investigators stated the emetogenicity of the chemotherapy administered; included an implicit or explicit definition of complete acute CINV response; described the antiemetic regimen in full; and reported the complete acute CINV response rate as a proportion. RESULTS: Twenty-five randomized studies, including eight published since 2009, met the criteria for inclusion in this systematic review. Prophylaxis with a 5-HT3 antagonist (granisetron or ondansetron or palonosetron or tropisetron) ± dexamethasone ± aprepitant is recommended for children receiving highly or moderately emetogenic chemotherapy. For children receiving chemotherapy of low emetogenicity, a 5-HT3 antagonist is recommended. CONCLUSIONS: The findings of several randomized trials were used to update recommendations for the prevention of acute CINV. However, significant research gaps remain and must be addressed before CINV control in children can be optimized.
Entities:
Keywords:
Antiemetics; Chemotherapy-induced nausea; Chemotherapy-induced vomiting; Pediatrics; Supportive care
Authors: R J Gralla; D Osoba; M G Kris; P Kirkbride; P J Hesketh; L W Chinnery; R Clark-Snow; D P Gill; S Groshen; S Grunberg; J M Koeller; G R Morrow; E A Perez; J H Silber; D G Pfister Journal: J Clin Oncol Date: 1999-09 Impact factor: 44.544
Authors: Karin Jordan; Fausto Roila; Alexander Molassiotis; Ernesto Maranzano; Rebecca A Clark-Snow; Petra Feyer Journal: Support Care Cancer Date: 2010-09-09 Impact factor: 3.603
Authors: Hyoung Jin Kang; Susan Loftus; Arlene Taylor; Cara DiCristina; Stuart Green; Christian Michel Zwaan Journal: Lancet Oncol Date: 2015-03-12 Impact factor: 41.316
Authors: C S Straathof; M J van den Bent; J Ma; P I Schmitz; J M Kros; G Stoter; C J Vecht; J H Schellens Journal: J Neurooncol Date: 1998-03 Impact factor: 4.130
Authors: Ana Carolina Sepúlveda-Vildósola; Yadira Betanzos-Cabrera; Graciela Gascón Lastiri; Hugo Rivera-Márquez; Miguel Angel Villasis-Keever; Volkmar Wanzke Del Angel; Fernando Cerecedo Díaz; Enrique López-Aguilar Journal: Arch Med Res Date: 2008-08 Impact factor: 2.235
Authors: O Alvarez; A Freeman; A Bedros; S K Call; J Volsch; O Kalbermatter; J Halverson; L Convy; L Cook; K Mick Journal: J Pediatr Hematol Oncol Date: 1995-05 Impact factor: 1.289
Authors: Priya Patel; Sara R Lavoratore; Jacqueline Flank; Meaghan Kemp; Ashlee Vennettilli; Helen Vol; Tracey Taylor; Elyse Zelunka; Anne Marie Maloney; Paul C Nathan; L Lee Dupuis Journal: Support Care Cancer Date: 2019-06-08 Impact factor: 3.603
Authors: L Lee Dupuis; Sadie Cook; Paula D Robinson; Deborah Tomlinson; Emily Vettese; Lillian Sung Journal: Pediatr Res Date: 2019-07-29 Impact factor: 3.756
Authors: L Lee Dupuis; Sabrina Boodhan; Lillian Sung; Carol Portwine; Richard Hain; Patricia McCarthy; Mark Holdsworth Journal: Pediatr Blood Cancer Date: 2011-04-04 Impact factor: 3.167
Authors: J Flank; T Schechter; P Gibson; D L Johnston; A D Orsey; C Portwine; L Sung; L L Dupuis Journal: Support Care Cancer Date: 2017-08-30 Impact factor: 3.603
Authors: Jennifer Seelisch; Lillian Sung; Michael J Kelly; Jennifer L Raybin; Melissa Beauchemin; Christopher C Dvorak; Katherine Patterson Kelly; Michael L Nieder; Robert B Noll; Jennifer Thackray; Nicole J Ullrich; Sandra Cabral; L Lee Dupuis; Paula D Robinson Journal: Pediatr Blood Cancer Date: 2018-09-26 Impact factor: 3.167